Emerging infectious diseases · 2010 · 140 citations · 28 references
Life SciencesInfectious DiseasesPharmacotherapyInfectious Disease EpidemiologyMolecular VirologyVirologyAntiviral ResistanceAntiviral TherapyInfluenza-like Illness SurveillanceTransplant Infectious ComplicationsViral EpidemiologyViral InfectionsAntiviral Resistance SurveillanceDrug Resistance MonitoringIn-hospital MortalityInfluenza Antiviral ResistanceInfluenza Antiviral TherapyPandemic Influenza SurveillancePost-transplant Infection SurveillanceViral Infection Surveillance
We describe laboratory-confirmed influenza A pandemic (H1N1) 2009 in 17 hospitalized recipients of a hematopoietic stem cell transplant (HSCT) (8 allogeneic) and in 15 patients with malignancy treated at 6 Australian tertiary centers during winter 2009. Ten (31.3%) patients were admitted to intensive care, and 9 of them were HSCT recipients. All recipients of allogeneic HSCT with infection <100 days posttransplantation or severe graft-versus-host disease were admitted to an intensive care unit. In-hospital mortality rate was 21.9% (7/32). The H275Y neuraminidase mutation, which confers oseltamivir resistance developed in 4 of 7 patients with PCR positive for influenza after > or = 4 days of oseltamivir therapy. Three of these 4 patients were critically ill. Oseltamivir resistance in 4 (13.3%) of 30 patients who were administered oseltamivir highlights the need for ongoing surveillance of such resistance and further research on optimal antiviral therapy in the immunocompromised.
28
Marcie Tomblyn, Tom Chiller, Hermann Einsele et al. · Biology of Blood and Marrow Transplantation · 2009 · 1.8K citations · Full text
Critically Ill Patients With 2009 Influenza A(H1N1) Infection in Canada
JAMA · 2009 · 1.4K citations